The authors performed a longitudinal multi-omics analysis on a large cohort of melanoma patients, either naïve or previously treated with anti-CTLA-4, revealing how tumor co-evolves with the antitumoral immune response during anti-PD-1 treatment. Here, CTLA4 is linked to melanoma.